Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacy > 301 IBD > Flashcards

301 IBD Flashcards

1
Q

What are the abdominopelvic regions?

A
  1. Right hypochondriac region
  2. Epigastric region
  3. Left hypochondriac region
  4. Right lumbar region
  5. Umbilical region
  6. Left lumbar region
  7. Right iliac region
  8. Hypogastric region
  9. Left iliac region
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does the sigmoidoscope work?

A

Passed through anus into colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does colonoscope work?

A

Passed through anus into colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sigmoidoscopy: procedure and outcomes

A
  1. Routine in patients with lower abdominal symptoms or in diarrhoea cases
  2. Normal mucosa is shiny with superficial vessels & no contact bleeding, biopsy if needed
    Can identify: colitis, polyps (+ removal), haemorrhoids, neoplasms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Flexible sigmoidoscopy: procedure and outcomes

A
  1. Reach up splenic flexure, requires bowel preparation, routine in patients w/ increased stool frequency/looseness/rectal bleeding
  2. Normal mucosa is shiny with superficial vessels & no contact bleeding, biopsy if needed
    Can identify: colitis, polyps (+ removal), haemorrhoids, neoplasms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Gastroscopy or OGD: procedure and outcomes

A
  1. Upper GI disorders, visual endoscopes relay colour images to HD monitor, therapeutic OGD treats upper GI bleeding & obstruction, requires fasting
  2. Can identify: reflex oesophagitis, gastritis, ulcers & cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Colonoscopy: procedure and outcomes

A
  1. Good visualisation of whole colon & terminal ileum, biopsies obtained, polyps removed, benign strictures dilated, malignant strictures stented, oral iron stopped 1 week prior, bowel cleanse required
  2. Can identify: cancer, polyps, diverticular disease, IBD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Proctoscopy: procedure and outcomes

A
  1. For all patients with history of bright red rectal bleeding to look for anorectal pathology, rigid sigmoidoscope is too narrow & long to enable adequate exam of anal canal
  2. Haemorrhoids are seen as purplish veins, fissures may be seen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is IBD?

A

Immune-mediated chronic intestinal condition
UC or CD
CUTE (colitis of uncertain type of etiology)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Possible causes of IBD

A

Genetics
Environment
Smoking
OCP
Appendectomy
Abx
NSAIDs
Diet
Infection
Gut microflora
Host immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Genome wide studies of IBD

A
  1. NOD 2/CARD15 on chromosome 16
  2. Autophagy genes (ATG16L1, IRGM)
  3. IL23 and Th17 cytokines
  4. HLA genes on chromosome 6 modifies disease
    - DRB0103 allele: aggressive UC, colonic CD
    - DRB    0103 and MICA010: perianal disease
    - DRM    0701: Ileal CD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Crohn’s disease immune response

A
  1. In Crohn’s disease, Th1 cells release cytokines (INF-gamma and TNF-alpha), which stimulate macrophages
  2. Macrophages release harmful substances such as free radicals, proteases & platelet-activating factor
  3. Leads to unregulated inflammation & tissue destruction
  4. This process contributes to the ongoing inflammation characteristic of CD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Colonic mucosa comparison: CD and UC

A
  1. CD: “cobble-stoning”, fat-wrapping with thicken colon wall & fissures
  2. UC: ulceration, surviving mucosa (pseudo-polyps), loss of haustra & crypt distortion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Extraintestinal symptoms of CD and UC

A

Eyes: episcleritis more in CD & uveitis & iritis more in UC
Mucocutaneous lesions
Skin effects
Weight loss
Anaemia
UC less associated w/ gallstones, fistulas or renal stones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Goals of IBD treatment

A
  • Reduce colorectal cancer risk
  • Treat & reduce intestinal inflammation
  • Promote mucosal healing
  • Maintain remission
  • Improve QoL
  • Treat complications
  • Replenish nutritional deficits
  • Address psychosocial issues
  • Minimise toxicity
  • Control & relieve symptoms
    Not curative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IBD pharmacological management

A

Anti-inflammatory drugs
Immunosuppressants
Biologics
Others (antibiotics, analgesics, vitamins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Crohn’s disease

A

Any part of GIT (mouth ulcers/anal skin tags)
‘Skip lesions’
Macrophage, neutrophils, T-lymphocytes involvement
Transmural inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What does Crohn’s cause?

A

Malabsorption (folate deficiency, decreased vitamin B12 (megaloblastic anaemia), decreased iron (iron deficiency anaemia))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What increases Crohn’s risk?

A

Made worse by smoking
Appendectomy increases risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the onset ages of Crohn’s

A

2 age peaks 15-30yo and 60-80yo

21
Q

Ulcerative colitis affects

A

Affects rectum, spreads to colon
Superficial mucosal inflammation
Continuous
Appendectomy appears ‘protective’

22
Q

Corticosteroids in IBD

A

Immunosuppressive, anti-inflammatory
Short courses to induce remission
Adverse effects with long term use (bone)
Slow tapering regimen vs rapid reduction
Ineffective in maintenance

23
Q

Aminosalicylates in UC

A

Sulfasalazine, olsalazine, balsalazine are pro-drugs (metabolised by bacteria in gut to form 5-ASA
Oral mesalazine rapidly absorbed in proximal SI & extensively metabolised (MR preparations designed to release mesalazine in distal lumen/colon (site of UC inflammation))

24
Q

Aminosalicylates contraindicated by and cause what S/Es

A

Patients allergic to aspirin
Blood dyscrasias, GI side effects

25
Q

Aminosalicylates MOA

A

Inhibits LT and prostanoid formation
Scavenges free radicals
Decreased neutrophil chemotaxis

26
Q

Thiopurines in IBD and risks

A

E.g. azathioprine, mercaptopurine
(Azathioprine is prodrug of mercaptopurine)
Unlicensed in IBD
Risk of pancreatitis

27
Q

Thiopurines MOA

A

Inhibits RNA synthesis
Modulate T cells

28
Q

What should be assessed before giving thiopurines?

A

TPMT activity (enzyme that breaks down this kind of drug, if they have polymorphism for this enzyme, it will be hepatotoxic)

29
Q

Methotrexate in IBD

A

No evidence in UC
Unlicensed in IBD
Steroid sparing effect
Antimetabolite

30
Q

Methotrexate MOA

A

Inhibits enzyme dihydrofolate reductase
Inhibits lymphocyte multiplication

31
Q

Methotrexate ADRs and interactions

A

Hepatotoxicity, pneumonitis
+ folic acid to alleviate GI ADR
Interactions with NSAIDs

32
Q

Ciclosporin MOA and evidence in IBD

A

Blocks T-lymphocytes
Prevents production of IL-2 and pro-inflammatory cytokines
No evidence in CD
Unlicensed in IBD

33
Q

Biologics in IBD

A

E.g. infliximab, adalimumab
Monoclonal antibodies
Increases risk of infection
TB screening necessary

34
Q

Biologics MOA

A

Neutralises TNFα
Interrupt the inflammatory cascade

35
Q

Suppository - site of action & disease extent

A

Rectum
Proctitis

36
Q

Foam (do not spread as far as enemas (due to low volume) but have better retention & acceptability) - site of action & disease extent

A

Sigmoid colon
Proctosigmoiditis

37
Q

Enema - site of action & disease extent

A

Descending colon to splenic flexure (in some cases to distal part of transverse colon)
Left-sided (distal) colitis

38
Q

Pentasa (500mg mesalazine)

A

Pressed tablet containing mix of drug microspheres with 1, 2 or 3 layers of ethylcellulose

39
Q

Octasa (800mg mesalazine)

A

Release of mesalazine only at pH above 7 (within terminal ileum & colon)

40
Q

Asacol (400mg mesazaline)

A

Released in terminal ileum & large bowel by effect of pH above 7, the Eudragit S coat disintegrates & releases active constituent

41
Q

IBD management

A

Colonoscopic surveillance after 10 years
Bone health: osteopenia & fracture risk
Growth & pubertal development

42
Q

What to avoid in ileostomy and jejunostomy?

A

Avoid enteric coated, MR preparations (active ingredient may not be at site of absorption long enough or may bypass completely), avoid prokinetics, laxatives

43
Q

Diverticulae

A

Increased intraluminal pressure, herniation of colonic mucosa through weak areas

44
Q

Diverticular disease

A

Problems caused by diverticular e.g. change in bowel habit, abdominal pain

45
Q

Diverticulitis

A

Acute inflammation of diverticulae

46
Q

Which is more common in the UK - UC or CD?

A

UC more common

47
Q

What GI symptoms do patients usually present with?

A

Diarrhoea, rectal bleeding, abdominal pain, weight loss, fatigue and fever
Crohn’s also anal fistulas, abscesses and rectal prolapse

48
Q

Are extra-GI symptoms more commonly found in UC or CD?

A

CD, more common before GI symptoms become more prominent
Examples:
CD: pauci-articular arthritis and erythema nodosum
UC: joint pain, swelling, and stiffness

49
Q

What side effects are commonly associated with aminosalicylates?

A

Indigestion, heartburn, feeling sick (nausea)
diarrhoea, being sick (vomiting), stomach (abdominal) pain, dizziness

50
Q

Name 2 types of orally administered medications that might be associate with problems in ileostomy patients

A

Enteric-coated & modified-release medicines are unsuitable as there may be insufficient release of the active ingredient

Pharmacy (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions